BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27374225)

  • 21. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
    Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
    Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
    Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
    Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
    Alonso CN; Longo PL; Gallego MS; Medina A; Felice MS
    Pediatr Blood Cancer; 2008 Apr; 50(4):869-71. PubMed ID: 18000862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular findings in childhood leukemia in Brazil: high frequency of MLL-ENL Fusion/t(11;19) in infant leukemia.
    Marques EA; Neves L; Fonseca TC; Lins MM; Pedrosa F; Lucena-Silva N
    J Pediatr Hematol Oncol; 2011 Aug; 33(6):470-4. PubMed ID: 21436736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
    Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells.
    Shah CA; Bei L; Wang H; Platanias LC; Eklund EA
    J Biol Chem; 2013 Nov; 288(45):32490-32505. PubMed ID: 24089521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9.
    Zhang LS; Kang X; Lu J; Zhang Y; Wu X; Wu G; Zheng J; Tuladhar R; Shi H; Wang Q; Morlock L; Yao H; Huang LJ; Maire P; Kim J; Williams N; Xu J; Chen C; Zhang CC; Lum L
    EBioMedicine; 2019 Jan; 39():145-158. PubMed ID: 30528456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression.
    Fleischmann KK; Pagel P; von Frowein J; Magg T; Roscher AA; Schmid I
    J Exp Clin Cancer Res; 2016 Jan; 35():9. PubMed ID: 26762252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
    Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia.
    Numata A; Kwok HS; Kawasaki A; Li J; Zhou QL; Kerry J; Benoukraf T; Bararia D; Li F; Ballabio E; Tapia M; Deshpande AJ; Welner RS; Delwel R; Yang H; Milne TA; Taneja R; Tenen DG
    Nat Commun; 2018 Apr; 9(1):1622. PubMed ID: 29692408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of HOXA9 activity by predominant expression of DACH1 against C/EBPα and GATA-1 in myeloid leukemia with MLL-AF9.
    Lee JW; Kim HS; Hwang J; Kim YH; Lim GY; Sohn WJ; Yoon SR; Kim JY; Park TS; Oh SH; Park KM; Choi SU; Ryoo ZY; Lee S
    Biochem Biophys Res Commun; 2012 Sep; 426(3):299-305. PubMed ID: 22902925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL-mediated leukemia.
    Nakamura A; Masuya M; Shinmei M; Tawara I; Nosaka T; Ono R
    Blood Adv; 2024 May; 8(9):2193-2206. PubMed ID: 38452334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes.
    Fleischmann KK; Pagel P; Schmid I; Roscher AA
    Mol Cancer; 2014 Feb; 13():27. PubMed ID: 24517546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation.
    Heuts BMH; Arza-Apalategi S; Alkema SG; Tijchon E; Jussen L; Bergevoet SM; van der Reijden BA; Martens JHA
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.